secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001493152-24-043933
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon Q3 net loss $4.9M; progressing toward Phase 3 for IMNN-001 in ovarian cancer
--------------------------------------------------------------------------------

- Net loss of $4.9M ($0.34 per share) vs $3.5M in Q3 2023; R&D expense $3.3M, G&A $1.7M.
- Cash, investments of $10.3M; expects to fund operations into Q3 2025.
- OVATION 2 topline: 11.1-month OS improvement, hazard ratio 0.74 in ITT; 15.7-month OS in per-protocol.
- Plan 500-patient Phase 3 study start Q1 2025; End-of-Phase 2 FDA meeting later in November 2024.
- Raised $10M gross proceeds in July 2024 registered direct offering; added General Counsel and SVP of Operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315224043933/0001493152-24-043933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315224043933/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-043933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer